European Multidisciplinary Meeting on Urological Cancers to be held in Barcelona

With the goal to deliver an in-depth review of the latest multi-modal management strategies for urological cancers, the 4th European Multidisciplinary Meeting on Urological Cancers (EMUC) will be held from 16 to 18 November 2012 in Barcelona, Spain.

 Co-organised by the European Association of Urology (EAU), the European Society for Medical Oncology (ESMO) and the European Society for Radiotherapy and Oncology (ESTRO), the two-a-half-day meeting will focus on the most recent management approaches for prostate, bladder and renal cancers. With a scientific programme that presents the views of urology, medical oncology and radiotherapy, sessions will begin with case presentations, followed by three state-of-the-art lectures by expert speakers from each discipline. A discussion forum and interactive voting will survey and evaluate audience response to the issues presented.

 "As shown in previous EMUC meetings, the multi-disciplinary strategies will be the main focus. It is our aim to closely examine the most effective and newest treatment tools and how various specialists work and collaborate to deliver high-quality healthcare," the organisers said in a press statement.

 To underscore the synergy among urologists, oncologists and radiologists, experts from and outside Europe are leading the discussions and providing the most up-to-date information on research outcomes, the assessment of current treatment standards, and the evaluation by specialists and urological cancer professionals.

First and second-day sessions will tackle management issues in prostate cancer (PCa) with the topics ranging from the multi-modal treatment of metastatic disease, bone-targeted therapies, and managing non-metastatic PCa, among other topics. The latest results from high-profile research studies in Europe and overseas will also be highlighted with expert lectures on the future of medical therapies, imaging, biomarkers, external beam radiotherapy and brachytherapy. Also in the agenda is an insightful 'Point-of-View' lecture series that will highlight controversial PCa issues.

Challenges in renal cell carcinoma and the role of surgery, medical strategy and new developments in radiotherapy will be taken up in the second day noon session, while locally advanced and oligometastatic bladder cancer will be examined in the last two sessions of the closing day.